

## QIBA CT Volumetry Biomarker Committee (BC)

17 August 2022 at 2 PM (CT)

Call Summary

### In attendance

Ritu Gill, MD, MPH (Co-Chair)

Rudresh Jarecha, MBBS, DNB, DMRE (Co-Chair)

Heang-Ping Chan, PhD

Vadivel Devaraju, PhD

Sean Fain, PhD

Mathis Konrad, MSc

Peter Ngum, MSc

Nancy Obuchowski, PhD

Kevin O'Donnell, MASc

Nicholas Petrick, PhD

### RSNA

Julie Lisiecki

**Moderator:** Dr. Jarecha

### Discussion Topics:

- Potential challenge similar to former QIBA Group 3A challenge
- Planning for Stage 4 Study

Additional details captured in [the recording](#) (Password: 51!u0y7!)

### Decisions/Action items:

#### Proposed challenge

- A challenge similar to 3A using the RIDER data on a smaller scale is under consideration
- Would like sites to use the same analysis software tool to limit variability
- This would provide an improved subset of data for Profile assessment
- Might include Dr. Samei's artificial simulated lesions from the phantom and clinical image datasets
- Work from Dr. Petrick's paper on the Lung Image Database Consortium ([LIDC](#)) assessment for reference: <https://www.sciencedirect.com/science/article/pii/S1076633206003825>.
- Dr. Gill to select the primary test dataset cases in September
  - Need to establish what the ground truth measurements are
  - Need testers to look for discrepancy cases and provide replacement lesions as needed
- Dr. Obuchowski to consider the number of radiologists needed to assess approximately 31 lesions and 14 modules
- Permission would be requested from participants to use segmentation and volume details of the lesions for publication
  - A potential publication would focus on analysis of observed inter- and intra- reader variability
- BC leaders to contact Mr. Buckler, as his company hosted the 3A Challenge data and completed the analysis
- Need to determine what type of data will be saved and where
- Training and clear instructions will be important to provide reproducible results
  - RIDER data contains lymph nodes, which increases complexity (will need to identify locations)

#### Planning for Stage 4 Study

- Request that QIBA Leadership would reach out to multiple sites
- Need to consider where data would be stored
  - A public cloud-based platform is needed
  - Consider asking 3 - 4 sites to collect clinical data for 30 patient lesions
  - Cross-check would be needed
- Details of organization and support TBD

### New action items:

- [Dr. Gill](#) to select some new cases for the RIDER dataset for the assessment procedure
- [Dr. Jarecha](#) to look for candidates to provide cross measurements to aid with determining ground truth

- [Dr. Jarecha](#) to begin drafting some study guidelines for the Stage 4 study
- [Dr. Obuchowski](#) to consider an appropriate assessment of the number of radiologists needed for approximately 31 lesions and 14 modules
- [Dr. Obuchowski](#) to email the Process Committee working document on study guidelines to Dr. Jarecha (note – this is still in process)

#### Ongoing action items:

- [Dr. Obuchowski](#) to determine if a revised coefficient of variation is needed and share revised sample size plan
- [Mr. O'Donnell](#) will double check with Dr. Obuchowski and Mr. Buckler to determine the ideal number of cases needed from RIDER data
- [Dr. Obuchowski](#) to adjust section 4.4 to account for precision and bias
- [Dr. Obuchowski's](#) revised sample size plan to be shared with Dr. Beaumont (for possible Stage 4 study)
- Suggestion to build use cases for the payers (future Profile version)
- Consider guidance or training data going forward for radiologists to become better “quantitators”
- Other questions to consider:
  - Should the Profile retain repeatability requirements for the radiologist?
  - Should a test of bias and linearity be added?
- Hurdle remains obtaining the test-retest data due to subject exposure to ionizing radiation

**Next Call:** to be determined via doodle poll (approximately one month from now) – mid September

#### Shared Google document / stage 4 planning:

[https://docs.google.com/document/d/1Wcmkzp8N\\_2ILL-FCyKNPwgsn1BJOs7Z9A1ZyTIkuGCo/edit](https://docs.google.com/document/d/1Wcmkzp8N_2ILL-FCyKNPwgsn1BJOs7Z9A1ZyTIkuGCo/edit)

- Group editing is welcome. All are invited to share ideas.

**Reference:** Data are available on the QIDW – <https://qidw.rsna.org/> under CT modality datasets

**Link to recording for 8/17/2022:** [https://rsna-org.zoom.us/rec/share/xapap\\_-MbDIhgUEA4ccV-1CZD0Fx91\\_wlvgyqPE5oy1yffDUQBsJ8qhlEIWiBZIF.IBDww\\_l1bK6sp5Kn?startTime=1660762207000](https://rsna-org.zoom.us/rec/share/xapap_-MbDIhgUEA4ccV-1CZD0Fx91_wlvgyqPE5oy1yffDUQBsJ8qhlEIWiBZIF.IBDww_l1bK6sp5Kn?startTime=1660762207000)

**Passcode:** 51!u0y7!